New US radiopharmaceutical for ovarian cancer treatment shows successful results, significantly limiting tumor growth and reducing tumor masses, as preclinical trials reveal new radiopharmaceuticals for ovarian cancer treatment with successful results New radiopharmaceuticals designed specifically for resistant ovarian cancers Conventional treatments in 25 minutes at a lower cost resulting in better efficiency compared to alternative methods This research was presented at the annual meeting of the Society for Nuclear Medicine and Molecular Imaging 2021, according to a report by time now news.
According to the American Cancer Society, more than 20,000 women are diagnosed with ovarian cancer each year and nearly 14,000 die from the disease. The five-year survival rate for ovarian cancer patients is 49.1% and is the fifth leading cause of cancer-related death among women.
In the study, the researchers used a new generative system to develop the treatment against positive ovarian cancer in experiments on mice, and the results demonstrated the success of the treatment and its effectiveness in affecting tumor growth and there were no adverse side effects from the treatment as determined by weight loss for all live animals.
Ovarian cancer is a cancerous tumor that affects women and the early signs and symptoms of ovarian cancer may be subtle, making it difficult to detect. It is sometimes overlooked or confused with something else. For this reason, ovarian cancer symptoms can sometimes appear out of nowhere, as if there were no warning signs.
Comments
Post a Comment